2013-09-13 17:33:27 - Recently published research from MarketLine, "Generics in Europe", is now available at Fast Market Research
Generics in Europe industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Europe generics market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
* For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by
the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
* The European generics market had total revenues of $41.2bn in 2012, representing a compound annual growth rate (CAGR) of 4.8% between 2008 and 2012.
* Market consumption volume increased with a CAGR of 1.8% between 2008-2012, to reach a total of 65.8% of total pharma volume in 2012.
* The performance of the market is forecast to accelerate, with an anticipated CAGR of 5% for the five-year period 2012 - 2017, which is expected to drive the market to a value of $52.7bn by the end of 2017.
Full Report Details at
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in Europe
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Europe
Leading company profiles reveal details of key generics market players' global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the Europe generics market with five year forecasts by both value and volume
Macroeconomic indicators provide insight into general trends within the Europe economy
Key Questions Answered
What was the size of the Europe generics market by value in 2012?
What will be the size of the Europe generics market in 2017?
What factors are affecting the strength of competition in the Europe generics market?
How has the market performed over the last five years?
What are the main segments that make up Europe's generics market?
Report Table of Contents:
TABLE OF CONTENTS
Market value forecast
Market volume forecast
Market value forecast
Market volume forecast
Five Forces Analysis
Threat of substitutes
Degree of rivalry
STADA Arzneimittel AG
Related MarketLine research
LIST OF TABLES
Table 1: Europe generics market value: $ million, 2008-12
Table 2: Europe generics market volume: % of total pharma volume, 2008-12
Table 3: Europe generics market geography segmentation: $ million, 2012
Table 4: Europe generics market value forecast: $ million, 2012-17
Table 5: Europe generics market volume forecast: % of total pharma volume, 2012-17
Table 6: Bayer AG: key facts
Table 7: Bayer AG: key financials ($)
Table 8: Bayer AG: key financials (EUR)
Table 9: Bayer AG: key financial ratios
Table 10: Novartis AG: key facts
Table 11: Novartis AG: key financials ($)
Table 12: Novartis AG: key financial ratios
Table 13: Sanofi: key facts
Table 14: Sanofi: key financials ($)
Table 15: Sanofi: key financials (EUR)
Table 16: Sanofi: key financial ratios
Table 17: STADA Arzneimittel AG: key facts
Table 18: STADA Arzneimittel AG: key financials ($)
Table 19: STADA Arzneimittel AG: key financials (EUR)
Table 20: STADA Arzneimittel AG: key financial ratios
LIST OF FIGURES
Figure 1: Europe generics market value: $ million, 2008-12
Figure 2: Europe generics market volume: % of total pharma volume, 2008-12
Figure 3: Europe generics market geography segmentation: % share, by value, 2012
Figure 4: Europe generics market value forecast: $ million, 2012-17
Figure 5: Europe generics market volume forecast: % of total pharma volume, 2012-17
Figure 6: Forces driving competition in the generics market in Europe, 2012
Figure 7: Drivers of buyer power in the generics market in Europe, 2012
Figure 8: Drivers of supplier power in the generics market in Europe, 2012
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Europe, 2012
Figure 10: Factors influencing the threat of substitutes in the generics market in Europe, 2012
Figure 11: Drivers of degree of rivalry in the generics market in Europe, 2012
Figure 12: Bayer AG: revenues & profitability
Figure 13: Bayer AG: assets & liabilities
Figure 14: Novartis AG: revenues & profitability
Figure 15: Novartis AG: assets & liabilities
Figure 16: Sanofi: revenues & profitability
Figure 17: Sanofi: assets & liabilities
Figure 18: STADA Arzneimittel AG: revenues & profitability
Figure 19: STADA Arzneimittel AG: assets & liabilities
MarketLine is a global publisher of company, industry and country information. Their clients operate across a wide variety of industries and job functions and range from multinational corporations right down to small businesses in both developed and developing economies. MarketLine users enjoy access to content that is trustworthy, up to date and reasonably priced and routinely turn to them as their first-stop resource for instantly accessible, reliable business information. View more research from MarketLine at www.fastmr.com/catalog/publishers.aspx?pubid=1034
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at www.fastmr.com
or call us at 1.800.844.8156.